📊 Key Data
  • $66.8 million raised since 2021 across four funding rounds.
  • 90% of cancer cases are solid tumors, which remain a major unmet medical need.
  • 2027 Series A financing planned as Laverock transitions to clinical-stage development.
🎯 Expert Consensus

Experts would likely conclude that Laverock Therapeutics' strategic leadership restructuring and transatlantic alliance position it strongly to advance CAR-T therapies for solid tumors, though success will depend on executing clinical trials and securing additional funding.

about 4 hours ago
Laverock Therapeutics Forges Transatlantic Alliance to Crack Solid Tumor Code

Laverock Therapeutics Forges Transatlantic Alliance to Crack Solid Tumor Code

LONDON, UK – November 16, 2026 – For the smart money in biotechnology, the low-hanging fruit has long been harvested. The initial wave of CAR-T cell therapies revolutionized the treatment of hematological malignancies, generating billions in value and fundamentally altering the standard of care for blood cancers. Yet, the holy grail of oncology—conquering solid tumors, which account for roughly 90% of all cancer cases—remains stubbornly out of reach.

Today, Laverock Therapeutics, a UK-based biotechnology spin-out, signaled its intent to break this biological deadlock. The company announced a sweeping leadership restructuring, appointing techbio leader Parker Moss as Chief Executive Officer and Wall Street veteran Paul J. Sekhri as Executive Chairman. Founding CEO David Venables will step down on December 31 following a transition period, while interim Chair Lisa Deschamps will remain on the Board as a Non-Executive Director.

As investors increasingly pivot away from the nebulous promises of "AI fatigue" and back toward tangible, clinical-stage fundamentals, Laverock's executive overhaul is a masterclass in corporate positioning. The company is actively building a transatlantic bridge, pairing deep British scientific leadership with prominent US corporate finance experience ahead of a highly anticipated Series A financing round planned for 2027.

The Transatlantic Blueprint: Bridging UK Techbio and Wall Street

The strategic rationale behind Laverock's new leadership is hiding in plain sight: to successfully transition from a preclinical research engine into a clinical-stage powerhouse, a company needs institutional US capital.

Paul J. Sekhri’s appointment as Executive Chairman brings nearly four decades of life sciences experience and a formidable Rolodex to the London-based firm. Sekhri is a known entity to global pharmaceutical partners and venture capitalists alike. Most recently, as Chairman of Longboard Pharmaceuticals, he oversaw its sale to Lundbeck for $2.6 billion in December 2024. His track record of raising massive capital—including roughly $400 million during his tenure at eGenesis—provides Laverock with the heavy-hitting financial stewardship required to navigate a challenging macroeconomic environment.

Parker Moss, stepping into the CEO role, represents the other half of this strategic equation. Moss arrives from Wellcome Leap, where he led a $150 million investment in RNA design and manufacturing technology for the R3G programme. His background, which includes leading corporate development at Exscientia through its acquisition by Recursion, bridges the gap between complex computational biology and clinical application.

"Laverock's gene control platform uses the cell's own regulatory machinery and is designed to improve CAR-T performance in solid tumours," Moss stated. "My priority is to bring our lead programmes into the clinic. With Paul in New York and our team in the UK, we are well placed to bring together investors and partners on both sides of the Atlantic."

This London-New York axis is built on a solid financial foundation. Since spinning out of Tropic Biosciences in 2021, Laverock has quietly amassed $66.8 million in total funding across four rounds, backed by a syndicate that includes Calculus Capital, Eli Lilly and Company, Mercia Ventures, and Eos Advisory.

Rewriting the Rules of CAR-T for Solid Tumors

The market's skepticism regarding cell therapies for solid tumors is well-earned. The tumor microenvironment (TME) is notoriously hostile, acting as an immunosuppressive fortress that exhausts engineered T-cells before they can mount a sustained attack. Furthermore, the heterogeneous nature of solid tumors often leads to antigen escape, while off-target toxicity remains a persistent threat to patient safety.

Laverock’s answer to this biological bottleneck is its proprietary Gene Editing induced Gene Silencing (GEiGS®) technology. Rather than relying on blunt-force gene knockouts, GEiGS utilizes recoded microRNAs (miRNAs) to hijack the cell’s endogenous regulatory mechanisms. This allows for programmable, tunable, and multiplex gene control.

In essence, Laverock is attempting to build a "smart" CAR-T cell—one that can dial specific genes up or down in response to the immunosuppressive cues of the tumor microenvironment. Preclinical data for their primary T-cell program (LKV201) has demonstrated enhanced tumor control in solid tumor models without compromising safety.

"CAR-T has changed the treatment of blood cancers but has yet to deliver in solid tumours, where most patients are," Sekhri noted regarding his appointment. "Laverock's gene control platform is one of the strongest answers to that problem I have seen, which is why I am here. Parker has the scientific depth and partnering experience to take it into the clinic, and I look forward to building the company with him."

With candidate selection for its ex vivo and in vivo CAR-T programs expected in the first half of 2027, Laverock is racing against an evolving competitive landscape. Giants like Kite Pharma and upstarts like Poseida Therapeutics and Lyell Immunopharma are all vying for dominance in the solid tumor space. However, Laverock's tunable approach offers a differentiated mechanism of action that could prove critical in preventing T-cell exhaustion.

The Strategic Pivot: Partnering the Macrophage Program

Beyond T-cells, Laverock has also applied its GEiGS platform to iPSC-derived macrophages (the LKV301 program). Macrophages naturally traffic to and infiltrate solid tumors better than T-cells, making them an attractive vehicle for advanced therapies.

However, engineering macrophages is notoriously complex and capital-intensive. Companies like Carisma Therapeutics have paved the way in the clinic, but the financial burn rate required to advance these programs is immense. Laverock's decision to actively seek a development partner for its engineered macrophage program is a shrewd capital allocation strategy.

By out-licensing or partnering the macrophage asset, Laverock can generate non-dilutive capital and validate its platform through a major pharma tie-up, all while focusing its internal venture capital on driving its lead CAR-T programs toward human trials. One life sciences venture partner familiar with the space noted that this dual-track strategy—internal development for CAR-T and external partnerships for macrophages—is exactly the kind of disciplined portfolio management that institutional investors demand in today's market.

The 2027 Catalyst: Racing Toward the Clinic

As we look toward the 2026-2027 investment landscape, the market is demanding more than just elegant science; it demands clinical execution. Laverock's recent expansion into in vivo programs for CAR-T and genetic medicine adds another layer of upside to its valuation. In vivo cell therapy—where the gene editing tools are delivered directly into the patient's body, eliminating the need for costly and time-consuming ex vivo cell manufacturing—is widely considered the future of the industry.

The leadership transition announced today is the catalyst that sets the stage for Laverock's next act. By bringing in Sekhri to court Wall Street and Moss to drive the scientific pipeline, the company is signaling that it is ready to graduate from a promising UK techbio spin-out to a global clinical contender.

Outgoing interim Chair Lisa Deschamps summarized the transition aptly: "In selecting Parker and Paul to lead the company in the next phase of growth, we have the right combination of scientific depth, operational focus and financing experience."

With candidate selection looming in H1 2027 and a Series A on the horizon, Laverock Therapeutics has positioned itself precisely where momentum investors are looking: at the intersection of a massive unmet medical need, a differentiated technology platform, and a leadership team with a proven history of lucrative exits.

Topics & Related

Event:
Leadership Change
Theme:
Drug Development
Sector:
Biotechnology

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55020